Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

Summary

Anbogen Therapeutics announced a Collaborative Research Agreement with the University of Tokyo to evaluate ABT-301 across multiple tumor types, aiming to accelerate human clinical indication expansion.